← Theranostic Atlas Therapy radar Imaging radar All targets Molecules Français Molecules
Flurpiridaz Target Myocardial perfusion Class Small molecule (pyridaben, complex I inhibitor) Other names BMS747158
1 ongoing trials
1 radiolabelled forms
1 approved products
126 publications (PubMed)
Structure 3D 2D
Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: PubChem (3D conformer computed by PubChem). Rotate with the mouse or a finger.
Properties (PubChem) Molecular formula C18H22ClFN2O3 Molar mass (g/mol) 368.8 Exact mass (Da) 368.1303 XLogP 3 H-bond donors 0 H-bond acceptors 5 Rotatable bonds 8 Heavy atoms 25 InChIKey RMXZKEPDYBTFOS-UHFFFAOYSA-N PubChem record CID 24864646 ↗ IUPAC name 2-tert-butyl-4-chloro-5-[[4-(2-fluoroethoxymethyl)phenyl]methoxy]pyridazin-3-one SMILES CC(C)(C)N1C(=O)C(=C(C=N1)OCC2=CC=C(C=C2)COCCF)Cl Radiolabelled forms Form Use Molar mass (labelled form) Ongoing trials Most advanced phase Approval [¹⁸F]flurpiridaz Imaging 367.8 1 Phase 2 PET perfusion (Cardiogen, Ruby-Fill, ¹³N-ammonia, Flyrcado) US EU FR
Atlas trials whose studied drug or title names this vector, with this radionuclide.
Other trials listing it among the interventions (comparator, associated scan) · 1 Published results · 1 2026-07 AURORA (obese patients) · positivePre-specified subgroup of 298 obese patients from the phase 3 trial: flurpiridaz PET meets its primary endpoint and is more sensitive than technetium scintigraphy for two of three readers. No loss of performance in obese patients. J Nucl Cardiol ↗
126 publications in PubMed for the query below; the most recent:
flurpiridaz[tiab]
[Nuclear medicine-necessity and opportunities in modern cardiology] Inn Med (Heidelb), 2026 Evaluation of Myocardial Blood Flow Using (18)F-flurpiridaz PET: Established Applications with Pharmacologic Stress and Roadmap for Exercise Stress Implementation Curr Cardiol Rep, 2026 Comparative diagnostic performance of [(18)F] flurpiridaz PET and SPECT myocardial perfusion imaging (MPI): a systematic review and meta-analysis Eur J Nucl Med Mol Imaging, 2026 Recent Progress in PET and SPECT Myocardial Perfusion Imaging: From Radiopharmaceuticals to Imaging Innovations Iran J Pharm Res, 2026 Unveiling silent CAD in an oncology patient: stress delayed defect filling of [¹⁸F]Flurpiridaz as a potential viability biomarker Eur J Nucl Med Mol Imaging, 2026 Transient ischemic dilation in the (18)F-Flurpiridaz positron emission tomography myocardial perfusion imaging era: Time to adopt radiotracer and stressor specific thresholds J Nucl Cardiol, 2026 Transient ischemic dilation with (18)F-flurpiridaz positron emission tomography: Establishing thresholds for a novel radiotracer J Nucl Cardiol, 2026 (18)F-flurpiridaz positron emission tomography myocardial blood flow in obese patients: Preserved diagnostic performance and promising perspectives for nuclear cardiology J Nucl Cardiol, 2026 Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.
Cite this page Flurpiridaz. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/flurpiridaz/ (accessed [date]).
A monitoring tool with no regulatory value: check every item at its source.